← Russell 3000 cross-section

BMY BRISTOL MYERS SQUIBB CO

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$137.4bn
Revenue TTM
$49.2bn
Net income TTM
$9.3bn
Free cash flow
$11.4bn
Composite score
Sector rank
#89

Valuation

P / E
14.8
EV / EBITDA
EV / sales
3.4
FCF yield
8.33%
Earnings yield vs 10-yr
2.03pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
18.9%
EBITDA margin
ROE
41.6%
ROIC
Revenue growth
3.1%

Insider activity, last 90 days

Net open-market
$-0.03m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

After adjusting for specified items, the increase in non-GAAP EPS of $0.58 and $0.36 for the second quarter of 2026 and year-to-date, respectively, was primarily due to the aforementioned Acquired IPRD charge and higher revenues, partially offset by the expiry of royalty income on diabetes products. United States • U.S. revenues increased 6% during the second quarter of 2026 and 2% year-to-date, reflecting higher demand and higher average net selling prices across the Growth Portfolio and for Eliquis , partially offset by the impact of generic erosion within the remainder of the Legacy Portfolio . …BRISTOL MYERS SQUIBB CO, 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →